Anavex (AVXL) Life Sciences announced that The Journal of Prevention of Alzheimer’s Disease, JPAD, has published peer-reviewed detailed results from the Phase IIb/III study evaluating oral blarcamesine for the treatment of early Alzheimer’s Disease, AD. Once daily oral blarcamesine, demonstrating a safety profile with no associated neuroimaging adverse events, significantly slowed clinical progression by 36.3% at 48 weeks with blarcamesine group as well as the prespecified SIGMAR1 wild-type gene group by 49.8% at 48 weeks on the prespecified primary cognitive endpoint ADAS-Cog13.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVXL:
- Largest borrow rate increases among liquid names
- Anavex announces 3 years of treatment with blarcamesine show reduced decline
- Anavex Life Sciences (AVXL) Alzheimer Treatment Sends the Stock to New Heights
- Biotech Alert: Searches spiking for these stocks today
- Anavex price target raised to $42 from $40 at H.C. Wainwright